First Trust NASDAQ Smart Grid ETF vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? First Trust NASDAQ Smart Grid ETF trades at $171.96 (market cap $12.08B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: First Trust NASDAQ Smart Grid ETF and Dr. Reddy's Laboratories Ltd Common Stock are close in size by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while First Trust NASDAQ Smart Grid ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Smart Grid ETF for 14 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| GRID | RDY | |
|---|---|---|
Market Cap | $12.08B | $10.61B |
Volume | 430,482 | 3,738,869 |
Sector | Sector/Thematic | Health |
52-Week High | $199.80 | $15.38 |
52-Week Low | $146.51 | $11.38 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | — | $10.51B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
GRID trades at $179.25, up 0.31% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock is positioned in the smart grid infrastructure sector, benefiting from AI-driven power buildout investments. Recent news highlights its exposure to infrastructure modernization and AI energy demand, though key financial ratios are not disclosed in the provided data.
Outlook is mixed: technicals suggest caution, but thematic tailwinds from AI infrastructure spending offer growth potential. Risks include sector competition and execution challenges. Investors should weigh near-term technical weakness against long-term infrastructure investment trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
First Trust NASDAQ Smart Grid Infrastructure ETF seeks to track companies involved in smart grid and electricity infrastructure. Its holdings include businesses related to power networks, energy management, and grid technologies.
Read more on GRID →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →